Latest News
Should CMS monitor biosimilar coverage on formularies?
The U.S. Department of Health and Human Services Office of Inspector General (OIG) released a study that found many Medicare Part D formularies included Humira Biosimilars for 2025. Humira is one of the best-selling prescription drugs in the world. However, Medicare Part D plans’ formularies restrict access to other biosimilars, which could have potential for savings for Medicare Part D. To read the OIG’s findings, click here…
The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; socialsecurityreport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or socialsecurityreport.org.